More than 200 preventive vaccines, developed by both industry and non-industry players, are being evaluated in clinical stages of development, claims Roots Analysis

Market-Research

Technical advances, especially in the field of biotechnology, have led to the development of several next generation preventive vaccines, including recombinant vaccines, viral vector based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunological memory.

To order this 250+ page report, which features 85+ figures and 125+ tables, please visit this link

The USD 94 billion (by 2030) financial opportunity within the global preventive vaccine market has been analyzed across the following segments:

Route of Administration

Intramuscular
Subcutaneous
Oral
Intravenous
Others

Type of Vaccine

Pneumococcal Conjugate Vaccine
Human Papilloma Virus Vaccine
Rotavirus Vaccine
Influenza Vaccine
MMR Vaccine
Tetanus and Diphtheria Booster Vaccine
Varicella Vaccine
DTaP-Hib-IPV Vaccine
DTaP-HepB-Hib-IPV Vaccine
Others

Type of Vaccine API

Live, Attenuated Vaccine
Inactivated Vaccine
Conjugate Vaccine
Subunit Vaccine
Toxoid Vaccine
Others

Target Patient Population
Pediatric Patients
Adults

Key Players
GlaxoSmithKline
Merck
Sanofi Pasteur
Pfizer
Emergent BioSolutions
CSL
Others

Key Geographical Regions
North America
Europe
Asia Pacific
Rest of the World

The Global Preventive Vaccines Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: